Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1992 2
1993 7
1994 4
1995 2
1996 3
1998 1
1999 1
2000 3
2001 5
2002 1
2003 4
2004 2
2005 2
2006 4
2007 1
2008 10
2009 3
2010 12
2011 8
2012 9
2013 17
2014 15
2015 25
2016 25
2017 19
2018 12
2019 10
2020 19
2021 18
2022 14
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Results by year

Filters applied: . Clear all
Page 1
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registry.
Shachar SS, Leviov M, Yerushalmi R, Drumea K, Tokar M, Soussan-Gutman L, Bareket-Samish A, Sonnenblick A, Ben-Baruch N, Evron E, Gal-Yam EN, Paluch-Shimon S, Bar-Sela G, Goldvaser H, Stemmer SM. Shachar SS, et al. Among authors: stemmer sm. NPJ Breast Cancer. 2023 Sep 30;9(1):79. doi: 10.1038/s41523-023-00586-3. NPJ Breast Cancer. 2023. PMID: 37775723 Free PMC article.
Probing Local Symmetry Breaking in a Ferroelectric Superconductor.
Zhu G, Combs NG, Salmani-Rezaie S, Jeong H, Russell R, Harter JW, Stemmer S. Zhu G, et al. Among authors: stemmer s. Microsc Microanal. 2023 Jul 22;29(Supplement_1):1628. doi: 10.1093/micmic/ozad067.836. Microsc Microanal. 2023. PMID: 37613823 No abstract available.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Jhaveri K, et al. Among authors: stemmer sm. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. Ann Oncol. 2023. PMID: 37597578 Free article. Clinical Trial.
262 results